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creativecommons.org/licenses/by-nc-nd/Abstract Background: Immune checkpoint inhibitors (ICIs) have revolutionised cancer ther-
apy but frequently cause immune-related adverse events (irAEs). Description of late-onset and
duration of irAEs in the literature is often incomplete.
Methods: To investigate reporting and incidence of late-onset and long-lasting irAEs, we re-
viewed all registration trials leading to ICI’s approval by the US FDA and/or EMA up to
December 2019. We analysed real-world data from all lung cancer (LC) and melanoma
(Mel) patients treated with approved ICIs at the University Hospital of Lausanne (CHUV)
from 2011 to 2019. To account for the immortal time bias, we used a time-dependent analysis
to assess the potential association between irAEs and overall survival (OS).f Oncology, Lausanne University Hospital, Switzerland.
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E. Ghisoni et al. / European Journal of Cancer 149 (2021) 153e164154Results: Duration of irAEs and proportion of patients with ongoing toxicities at data cut-off
were not specified in 56/62 (90%) publications of ICIs registration trials. In our real-world
analysis, including 437 patients (217 LC, 220 Mel), 229 (52.4%) experienced at least one grade
2 toxicity, for a total of 318 reported irAEs, of which 112 (35.2%) were long-lasting (6
months) and about 40% were ongoing at a median follow-up of 369 days [194e695] or patient
death. The cumulative probability of irAE onset from treatment initiation was 42.8%, 51.0%
and 57.3% at 6, 12 and 24 months, respectively. The rate of ongoing toxicity from the time of
first toxicity onset was 42.8%, 38.4% and 35.7% at 6, 12 and 24 months. Time-dependent anal-
ysis showed no significant association between the incidence of irAEs and OS in both cohorts
(log Rank p Z 0.67 and 0.19 for LC and Mel, respectively).
Conclusions: Late-onset and long-lasting irAEs are underreported but common events during
ICIs therapy. Time-dependent survival analysis is advocated to assess their impact on OS.
Real-world evidence is warranted to fully capture and characterise late-onset and long-
lasting irAEs in order to implement appropriate strategies for patient surveillance and
follow-up.
ª 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Immune checkpoint inhibitors (ICIs) that target
programmed cell death-1 (PD-1), programmed cell
death-ligand 1 (PD-L1), or cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) have revolutionised
cancer therapy. In the last five years, three PD-1 in-
hibitors (nivolumab, pembrolizumab and cemiplimab),
three PD-L1 inhibitors (atezolizumab, avelumab and
durvalumab) and one anti-CTLA-4 (ipilimumab) have
been approved by the US Food and Drug Adminis-
tration (FDA) and/or the European Medicines Agency
(EMA) for various indications and disease settings.
Although in many cases ICIs are not associated with
relevant toxicities and are usually well-tolerated
treatments, rare but severe immune-related adverse
events (irAEs) can occur [1,2]. In a recent meta-anal-
ysis, including more than 18,000 patients, 66% of
patients were found to develop at least one adverse
event (AE) of any grade (G) and 14% of G3 or
higher [3e7]. These above-mentioned irAEs can
remain incompletely resolved or resolved with chronic
sequelae, and exert a significant impact on patients
and their caregivers [8].
Traditionally, safety assessments in clinical trials
have primarily aimed to capture acute and life-
threatening adverse events during short-course chemo-
therapy and for a limited time thereafter. With the
advent of ICIs, however, there is a growing awareness
that safety assessments need to capture chronic and late-
onset toxicities that may develop several months or
years from drug exposure. In this new scenario, less
severe toxicities can constitute substantial threats to the
quality of life (QoL) and compliance with therapy,
thereby also affecting full treatment benefits [9]. Despitewell-accepted international standards (Common Ter-
minology Criteria for Adverse Events e CTCAE),
reporting of toxicity in clinical trials of new anticancer
agents remains difficult, especially in terms of duration
of AEs, including long-lasting and chronic events [10].
Time of irAEs onset and duration of toxicities are
mainly extrapolated from meta-analysis and reviews of
the literature with a wide variability of settings. In some
exceptional cases, the onset of rare events is described
>50 weeks after ICI initiation [11,12]. In addition,
publications of ICI(s) trial primary analysis are often
based on a limited follow-up, further underestimating
the occurrence and the duration of late-onset
toxicity [13,14]. Intriguingly, it has been hypothesised
that patients experiencing these irAEs might have a
better outcome than patients without toxicities, likely
reflecting a more competent/treatment-responsive im-
mune system or cross-reactivity between tumour and
host tissue [15e17]. Previous articles have investigated
this issue with conflicting results, especially when a land-
mark approach was used to overcome the so-called
‘immortal time bias’ [18e20].
In order to describe the completeness of irAEs
reporting, with particular attention to long-lasting and
late-onset irAEs, we reviewed all published registration
trials, which led to ICI’s approval by Food and Drug
Administration (FDA) and European Medicines
Agency (EMA) up to December 2019. The identified
lack of long-lasting and late-onset irAE prompted us
to use the data obtained from a large database of
electronic patient records at our Institution to provide
one of the first real-world analysis in an unselected
patient population. We then assessed the potential
correlation between irAEs onset and overall survival
(OS) using a time-dependent model to properly
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onset toxicities.2. Methods
2.1. Review of ICIs registrative trials
FDA and EMA regulation lists were searched for
approved ICIs up to December 2019, including any
tumour type and stage of the disease. Namely, seven
different treatments were included in this analysis: ipi-
limumab, pembrolizumab, nivolumab, avelumab, dur-
valumab, atezolizumab and ipilimumabenivolumab
combination. The corresponding registrational trial(s)
was retrieved for each approval. A dedicated case report
form (CRF) was used to collect data for each selected
paper in an electronic database. For each study, the
following information was recorded: date of publica-
tion, date of FDA and/or EMA approval, number of
patients treated in the ICI arm, median follow-up (FU),
number of patients ongoing at data cut-off and
description of irAE duration. For all the relevant data,
two investigators reviewed each selected paper. Any
discrepancy was resolved by discussion with a third se-
nior investigator. For all records, secondary publica-
tions with updated FU and data regarding toxicities
duration were searched in PubMed, by using the name
of the drug(s) and/or tumour type and/or the name of
authors of the primary publication and/or the study
acronym/code, when available.2.2. Real-world data collection
Electronic health records (EHR) of adult patients with
advanced melanoma (Mel) or lung cancer (LC) that
were treated with ICIs in the Medical Oncology
department at the University Hospital of Lausanne
(CHUV) from February 2011 to December 2019 were
retrieved using an application developed internally
(Virtual Trial). This application preprocesses unstruc-
tured texts from the EHR and automatically assigns
cancer diagnosis or TNMs using text-mining algorithms.
A graphical user interface helps validate the predictions
and visualise the data for patient selection. The appli-
cation also includes text search functions that use reg-
ular expressions for pattern detection of irAEs.
Clinicians diagnosed irAEs during treatment, and the
related details were captured by four physicians inde-
pendently using the aforementioned application. Any
discrepancy between physicians was resolved by dis-
cussion with senior clinicians. A protocol for retro-
spective data analysis for scientific purposes was
approved by the local ethics committee (CER-VD) on
the 12th of February 2020.
Patients were excluded from the analysis if: (i) treated
in a phase 1 trial; (ii) treated with an ICI combination,including an investigational ICI; (iii) treated in phase 2
or 3 study with approved ICIs but whose results are
unpublished or in a double-blind phase 3 study where
treatment allocation cannot be resolved; (iv) refused the
general consent for the further use of coded personal
data for research purposes; (v) have a FU  28 days or
have been lost to FU (Online Suppl. Fig. 1). The
following data were recorded: patients demographics,
diagnosis, treatment setting, type of ICI(s) received,
duration of each line of treatment, the incidence of any
irAEs of G2 or higher, time to onset and duration of
each irAE, use of steroids (topic and/or systemic) and of
second-line immune-modulating agents. IrAEs were
categorised by system organ class according to common
terminology criteria for adverse events version 5.0
[CTCAE v5.0] (Online Supplementary material).
2.3. Statistical analysis
Descriptive statistics were computed in R and SPSS
using built-in functions to assess patient, treatment and
irAE characteristics. Graphs were produced using SPSS
or the ggplot2 package in R. Comparisons between
types of irAEs in LC and Mel were performed using
Fisher exact tests for each category of irAEs. A log10
transformation was applied for normalisation of the
onset time of irAEs. Pairwise comparison of irAE onset
times was performed using the Tukey HSD test with p-
value correction for multiple testing. The conditional
probability of experiencing a second toxicity after a
second ICI treatment was assessed using the Fisher
exact test. The KaplaneMeier time-to-event estimator
was used to assess the cumulative probability of toxic-
ities while on treatment, considering the first line only. If
a subsequent line of treatment was given, the patient was
censored at the time of the second line initiation and
other potential irAEs associated with the second treat-
ment line were not taken into account. In the case of the
ipilimumab/nivolumab regimen, patients were censored
after the end of the nivolumab maintenance. The time to
onset of the irAE was defined as the time interval be-
tween ICI initiation (i.e. the first infusion) and the time
at which the first abnormal clinical or laboratory find-
ings related to a G2 or higher irAE occurred. Explor-
atory analysis of the association between the occurrence
of adverse events and OS was performed independently
in two subgroups (advanced lung cancer and advanced
melanoma). Uveal melanoma and small-cell lung cancer
(SCLC) were excluded, as well as (neo)adjuvant treat-
ments (N Z 44 and N Z 16 for Melanoma and Lung,
respectively). Only first line ICI-based treatments were
retained, when patients received several lines of ICI-
containing regimens (Online Suppl. Fig. 1).
KaplaneMeier curves were used to describe the survival
probability of patients who experienced at least 1
adverse event compared to patients who did not. Using
the survival and survminer packages in R, two Cox
E. Ghisoni et al. / European Journal of Cancer 149 (2021) 153e164156models were applied: (1) a standard Cox model
considering irAE occurrence as fixed variable and (2) a
Cox model, including toxicity occurrence as a time-
dependent covariate.3. Results
3.1. Review of ICI registrative trials
We found 62 publications, corresponding to 27 different
ICIs indications, involving 130953 patients (Online
Supplementary Table 1). Among 56 publications with
available information, median follow-up (mFU) was
12.1 months (interquartile range [IQR] 9.1e15). The
mFU time was particularly short for the studies leading
to ICI approval by FDA fast-track procedure (10.2
months, IQR 5e11.9), compared to those approved by
regular course (15.2 months, IQR 12e16.2, p < 0.001).
In 51/62 publications (82.2%), treatment was still
ongoing at data cut-off in a non-negligible proportion of
patients (median 23.5%, range 1%e63%). Duration of
irAEs and proportion of patients with ongoing toxicity
at data cut-off were not specified in 56 publications
(90.3%). In the remaining 6 publications, 3% up to 66%
of patients had ongoing irAEs at data cut-off, including
fatigue, endocrine dysfunctions, skin alterations,
gastrointestinal, hepatic and neurological toxicities.
Detailed results are reported in online Supplementary
Table 2. Secondary publications reporting toxicity data
were available in 25/62 cases (40.3%) and showed that
even at longer follow-up (median 23 months, IQR
15.6e27.6) the proportion of patients with ongoing
irAE was significant (median 13%, range 1%e23%).
Among secondary publications, only 6/25 studies (24%)
presented an update regarding the duration of irAEs,
and in all cases, the above-mentioned toxicities were still
ongoing.3.2. Real-world patient and treatment characteristics
In total, 622 patients (342 lung cancers [LC] and 280
melanoma [Mel]) treated with ICIs were identified. Of
these, 185 patients were removed due to exclusion
criteria. 437 patients were included in the final analysis.
Of these, 220 (50.3%) presented with Mel and 217
(49.7%) with LC. As some patients received more than
one treatment line, we considered a total of 532 ICI
treatments (242 for LC and 290 for Mel, of which 43 and
15 were in the context of a clinical trial, respectively).
Most of the treatments were given in the metastatic
setting (466, 88.6%). Nineteen (7.9%) LC patients
received treatment for locally advanced disease in an
adjuvant setting after surgery, or as consolidation after
chemo-radiation and 47 (16.2%) Mel patients received
adjuvant treatment.The most frequent treatment was anti-PD1 ICI
(n Z 247, 46.4%) followed by combination of anti
CTLA4-anti PD(L)1 (n Z 116, 21.8%), anti-CTLA4
alone (n Z 74, 13.9%), anti-PDL1 (n Z 48, 9.0%) and
combination of anti PD(L)1 and chemotherapy (CT,
þ/ bevacizumab) (n Z 47, 8.8%).
The median treatment duration was 84 days [IQR
42e252]. The median duration of the different ICI and
ICI-containing regimens reflected the indications and
disease settings they were applied in. The longest treat-
ments were the PDL1 monotherapies (median 237 days;
[IQR96e364]) and a combination of anti-PD(L)1 andCT
(þ/ bevacizumab) (median 160 days; [IQR 109e283]),
followed by anti-PD1 monotherapy (126 days; [IQR
54e318]), a combinationof anti-CTLA4andanti-PD(L)1
(62 days; [IQR 21e158]) and anti- CTLA4 alone (62 days;
[IQR 29e64]). Characteristics of patients and treatments
included in the analysis are reported in Table 1.
3.3. Incidence of immune-related adverse events
For a total of 318 reported G  2 irAEs in our study
population, 229 patients (52.4%) experienced at least
one G  2 toxicity. Of these, 189 (59.4%) were G2, 110
(34.6%) G3, 17 (5.3%) G4 and 2 G5 fatal events were
recorded (1 pneumonitis and 1 colitis). The most
common irAEs were endocrine disorders (n Z 71,
22.3%), followed by skin toxicity (n Z 63, 19.8%)
gastrointestinal toxicities (n Z 57, 17.9%), pulmonary
(n Z 45, 14.2%) and hepatitis (n Z 29, 9.1%). 140
toxicities lead to treatment discontinuation or tempo-
rary interruption (26.3%), out of which 44 (31.4%)
occurred in LC and 96 (68.5%) in Mel patients. Of
these, the majority were pneumonitis (n Z 32, 22.9%)
and colitis (n Z 29, 20.7%). The regimen most
frequently associated with irAEs was the anti-CTLA4-
anti-PD(L)1 combination, with 69% of patients expe-
riencing at least one irAE G  2, followed by anti
CTLA4 (55%), anti-PD-L1 (50%), anti-PD1 (34%) and
ICI þ CT (28%). All toxicities and their relative inci-
dence are listed in Table 2. Gastrointestinal irAEs and
hepatitis occurred more frequently in the Mel group
compared to LC (21% and 12% versus 11% and 2%
respectively, p < 0.05), while pneumonitis and rheu-
matological irAEs were more frequent in LC (29% and
12% versus 8% and 4%, p < 0.01). Incidence of irAEs
types in LC and Mel subgroups are represented in
Fig. 1. Thirty-six patients were rechallenged with a
second ICI line after having developed a G  2 toxicity
during the first treatment and of these 13/36 (36%) had
a second toxic event. Fifty patients received a subse-
quent ICI regimen without any previous irAE and 15/
50 (30%) developed a G  2 irAE at this point. The
difference in the conditional probability of making
toxicity in these two subgroups turned out to be non-
significant (p Z 0.6427).
Table 1
Characteristics of patients and treatments included in the analysis.
Number of patients Melanoma (n Z 220) Lung cancer (n Z 217) All (n Z 437)
Median age, years [minemax] 66 [55e75] 65 [59e71] 66 [57e73]
Sex
Female 89 (40.5%) 83 (38.2%) 172 (39.4%)
Male 131 (59.5%) 134 (61.8%) 265 (60.6%)
Number of patients with at least one irAEs ‡ G2 143 (65%) 86 (39.6%) 229 (52.4%)
Number of treatmentsa Melanoma (n Z 290) Lung cancer (n Z 242) All (n Z 532)
Treatment setting
Adjuvant 47 (16.2%) 19 (7.9%) 66 (12.4%)
Metastatic 243 (83.8%) 223 (91.9%) 466 (87.6%)
Treatment types
Anti-PD1 123 (42.4%) 124 (51.2%) 247 (46.4%)
Anti-PDL1 0 48 (19.8%) 48 (9.0%)
Anti-CTLA4 73 (25.2%) 1 (0.4%) 74 (13.9%)
Anti-CTLA4-antiPD(L)1 94 (32.4%) 22 (9.1%) 116 (21.8%)
Anti-PD(L)1-CT 0 47 (19.4%) 47 (8.8%)
Median treatment duration, days 64 [24e194] 141 [52e328] 84 [42e252]
Anti-PD1 138 [59e315] 118 [51e320] 126 [54e318]
Anti-PDL1 NA 237 [96e364] 237 [95e364]
Anti-CTLA4 62 [28e64] 750 [750-750] 62 [29e64]
Anti-CTLA4-antiPD(L)1 63 [21e173] 46 [23e75] 62 [21e158]
Anti-PD(L)1-CT NA 160 [109e283] 160 [109e283]
Median follow-up, days 444 [243e901] 308 [169e553] 369 [194e695]
Anti-PD1 376 [194e573] 336 [167e598] 350 [179e593]
Anti-PDL1 NA 385 [235e591] 385 [235e591]
Anti-CTLA4 627 [241e1462] 1688 [1688-1688] 652 [244e1486]
Anti-CTLA4-antiPD(L)1 544 [269e907 ] 215 [108e367] 445 [240e875]
Anti-PD(L)1-CT NA 258 [179e404] 258 [179e404]
Number of treatments stopped due to irAEs 96 (33.1%) 44 (18.2%) 140 (26.3%)
Anti-PD1 28 (29.2%) 20 (45.5%) 48 (34.3%)
Anti-PDL1 NA 9 (20.5%) 9 (6.4%)
Anti-CTLA4 25 (26.0%) 0 25 (17.9%)
Anti-CTLA4-antiPD(L)1 43 (44.8%) 8 (18.2%) 51 (36.4%)
Anti-PD(L)1-CT NA 7 (15.9%) 7 (5.0%)
Data are reported as median values with [25th and 75th IQR] or as patient counts with (% of total per column). NA Z not applicable.
a Some patients received more than one treatment line.
Table 2
Characteristics of the irAEs included in the analysis.
Melanoma Lung cancer All
Any irAEs ‡ G2 220 98 318
irAEs G2 128 (58.2%) 61 (62.2%) 189 (59.4%)
irAEs G3 78 (35.5%) 32 (32.7%) 110 (34.6%)
irAEs G4 13 (5.9%) 4 (4.1%) 17 (5.3%)
irAEs G5 1 (0.5%) 1 (1.0%) 2 (0.6%)
Type of irAEs ‡ G2
Skin 45 (20.5%) 18 (18.4%) 63 (19.8%)
Endocrine 53 (24.1%) 18 (18.4%) 71 (22.3%)
Pneumonitis 17 (7.7%) 28 (28.6%) 45 (14.2%)
Hepatitis 27 (12.3%) 2 (2.0%) 29 (9.1%)
Gastrointestinal 46 (20.9%) 11 (11.2%) 57 (17.9%)
Pancreatitis 5 (2.3%) 1 (1.0%) 6 (1.9%)
Rheumatological 8 (3.6%) 12 (12.2%) 20 (6.3%)
Neurological 8 (3.6%) 2 (2.0%) 10 (3.1%)
Nephrological 3 (1.4%) 2 (2.0%) 5 (1.6%)
Haematological 2 (0.9%) 1 (1.0%) 3 (0.9%)
Cardiac 2 (0.9%) 0 2 (0.6%)
Other 4 (1.8%) 3 (3.1%) 7 (2.2%)
irAEs ongoing at data cut-off or death 66 (30.0%) 62 (63.3%) 128 (40.3%)
Data are reported as patient counts with (% of total per column).
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Fig. 1. Total number of specific irAEs G  2 according to cancer and treatment types. Symbol ) indicates a significant difference between
the two subgroups (Mel and LC): pneumonitis, rheumatological, gastrointestinal and hepatitis, all with p < 0.05 (using Fisher exact tests).
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The median irAE onset time was 63 days [IQR 29e122]
after the initiation of an ICI treatment. Comparisons
between categories of irAEs onset time showed in LC a
trend for skin toxicities to appear sooner than endo-
crine irAEs (p Z 0.053) and pneumonitis (p Z 0.06)
(Fig. 2). The distribution of irAEs onset times was
more homogenous in Mel with no statisticallyFig. 2. Boxplots displaying irAEs onset time on a logarithmic scale acc
according to the global median onset time. Points show individual ons
colour in this figure legend, the reader is referred to the Web versionsignificant difference found. In total, 6.9% of all irAEs
started one year after treatment initiation. All median
times to onset and duration of irAEs are described in
Supplementary Table 3. Regarding treatment type PD1,
PD-L1 and ICI þ CT were more prone to result in late-
onset irAEs, possibly be explained by the longer
treatment duration (Table 1). However, relatively small
numbers in each subgroup preclude drawing statistical
significance.ording to toxicity type. Toxicities are presented in ascending order
et times per treatment type. (For interpretation of the references to
of this article.)
E. Ghisoni et al. / European Journal of Cancer 149 (2021) 153e164 159The cumulative probability of onset of first toxicity
since treatment initiation was 42.8%, 51% and 57.3% at
6, 12 and 24 months respectively (Fig. 3A).
With an mFU of 369 days [IQR 194e695], we observed
a median duration of all irAEs of 98 days [IQR 28e279].
In particular, median time to resolution for endocrine
irAEs was not reached and it was 93 days for pulmonary,
44 days for skin and 39 days for gastrointestinal
toxicities (Supplementary Fig. 1). Of the 318 irAEs recor-
ded, 112 (35.2%) were long-lasting (duration  6 months)
and 128 (40.3%) were ongoing at our data cutoff or patient
death. Of these, the majority were endocrine irAEsFig. 3. Kaplan-Meyer curves representing the cumulative probability
toxicity since toxicity onset (B) in our study population.(n Z 69, 53.9%), skin toxicities (n Z 20, 15.6%), rheuma-
tological (nZ 14, 10.9%) and pneumonitis (nZ 11, 8.6%).
We then calculated the cumulative probability of ongoing
toxicity for patients still on ICI treatment and found that
this probability remains relatively stable with only a slight
increase over time (risk of 42,8% at 6 months, 38,4% at 12
months and 35,7% at 24 months, respectively) (Fig. 3 B).
3.5. Correlation between irAEs and OS
We then investigated whether the onset of any irAE(s)
correlated with overall survival (OS) benefit in our studyof toxicity since treatment start (A) and probability of ongoing
E. Ghisoni et al. / European Journal of Cancer 149 (2021) 153e164160population (Mel and LC cohorts). Standard Cox model
resulted in an apparent statistical significant benefit in
OS for both LC and Mel subgroups of patients who
developed a toxicity G  2 (HR 0.53 [95%CI 0.33e0.86],
p Z 0.0069 and HR 0.56 [95%CI 0.36e0.88], p Z 0.013,
respectively, Fig. 4A and C). By contrast, the corrected
Cox model, including toxicity as time-dependent co-
variate failed to retain the significant difference between
the two subgroups (HR 1.11 [95%CI 0.68e1.80],
p Z 0.67 and HR 0.74 [95%CI 0.47e1.16], p Z 0.19)
(Fig. 4B and D).4. Discussion
A comprehensive analysis of irAEs in clinical trials is
critical, as the results constitute an important reference
for clinicians. However, the need to quickly provide
potentially curative treatments to patients has prompted
regulatory agencies to develop fast track approval pro-
grams, which, although necessary, have the drawback ofFig. 4. Correlation between Overall Survival (OS) and immune-related to
D: advanced/metastatic melanoma cohort. (A, C): OS according to sta
(B, D): OS considering irAE onset as a time-dependent covariate.potentially underestimating late-onset adverse events, as
well as the long-term impact of chronic toxicities.
In our systematic review of pivotal trials leading to
ICI approval, the information regarding the duration of
irAEs and the proportion of patients with ongoing
toxicity at data cut-off was not specified in 90% of the
studies. Moreover, median follow-up was relatively
short and in more than 80% of the studies, treatments
were still ongoing at data cut-off in a significant pro-
portion of patients. We believe that accurate evaluation
and description of toxicity is essential to define treat-
ment value. Toxicity is among the parameters included
in the ASCO value framework [21,22]. Specifically, in
the case of unresolved symptomatic toxicities one year
after treatment completion, 5 points should be sub-
tracted from the clinical benefit score. Similarly, the
NCCN and ESMO Magnitude of Clinical Benefit Scale
(MCBS) include safety among the five key value mea-
sures, and the total score should be decreased for sig-
nificant chronic or long-term toxicities [23,24].
Consequently, if the information is lacking in thexicities (irAEs). (A, B): advanced/metastatic lung cancer cohort. C,
ndard Cox model considering irAE occurrence as a fixed variable;
E. Ghisoni et al. / European Journal of Cancer 149 (2021) 153e164 161publication, the score cannot be accurately calculated,
and the value of treatment can be overestimated.
Indeed, in several tumours, immunotherapy is associ-
ated with a significant increase in the chance of long-
term survival and this unprecedented benefit reason-
ably outweighs the uncommon risks of long-term tox-
icities. However, this issue will be more relevant
following ICI approvals in the adjuvant setting, where
the threshold of patients’ willingness to accept the risk
of long-term toxicity may probably be lower compared
to the advanced disease setting.
As already highlighted for haematological malig-
nancies, the need to revise principles for monitoring
safety and tolerability in pre-marketing trials and post-
marketing follow-up studies is urgent for new standard-
of-care treatments, including ICIs [25]. Nevertheless, the
need for efficient drug development, combined with the
financial constraints of prolonged patient monitoring
within trials, increases the relevance and need for more
extensive use of real-world evidence for long-term post-
marketing surveillance. In our real-world data analysis,
the cumulative incidence of any irAEs G  2 was 52%,
and one-third of our patients experienced at least one
G  3 adverse event, in line with the findings of the
recent systematic review by Wang and colleagues [3].
These numbers can be important to share with patients
before they begin treatment with ICIs. Incidence of
toxicities according to treatment type in our series was
consistent with results from 3 previous studies: the anti-
CTLA4-anti-PD(L)1 combination is the most toxic
treatment, followed by anti CTLA4, while anti-PD1
shows the best safety profile for irAEs [1,26,27].
Furthermore, organ-specific irAE distribution according
to treatment type and differences between melanoma
and lung cancer were in accordance with previous re-
ports (i.e. higher incidence of pneumonitis in lung cancer
and gastrointestinal toxicities in melanoma) and mainly
dependent on the agents used [1]. Interestingly, the
conditional probability of developing toxicity during a
subsequent line of ICI treatment did not differ between
patients who experienced an irAE during the first line
and patients who did not. However, this finding could
be explained by the selection bias in re-challenging pa-
tients who already had severe toxicity with first-line
ICI(s). As per guidelines, only patients with moderate
toxicity (G2) and completely resolved ones have been
rechallenged with a second ICI line [4,6].
Of note, the present study yielded three important
findings regarding ICIuse and irAEs in the real-life setting
among patients withmelanoma and lung cancer. First, we
found that the time to onset of irAEs varies considerably
and is widely distributed over time, with late-onset tox-
icities that can appear up to 2 years after the first-treat-
ment initiation. Even if a trend for a longer time to onset
was observed for endocrine irAEs and pneumonitis
compared to skin andGI irAEs, no statistically significant
difference was found. Furthermore, the cumulativeprobability of onset of first toxicity in our study popula-
tion was 42.8%, 51% and 57.3% at 6, 12 and 24 months
respectively. These numbers are even more relevant if we
consider the mFU of ICI pivotal trials (12 months),
meaning that a significant proportion of late-onset irAEs
could not be captured in these trials. These results un-
derline once more that patients receiving ICI(s) should be
regularly educated about the probability of developing
irAEs and monitored for treatment-related
complications since we show that late-onset irAEs are
more common than previous evidence suggested.
Second, in our cohort, about 35% of irAEs lasted 6
months, and about 40% were ongoing at our data cutoff
or patient death. The probability of ongoing toxicity
from the onset was 42.8%, 38.4% and 35.7% at 6, 12 and
24 months respectively. The potential occurrence of
long-lasting skin, endocrine, rheumatological, neuro-
logical or nephrological toxicities is a relevant issue for
both patients and caregivers, which definitely warrants
discussion during medical visits. This point is even more
relevant considering that in our study we captured only
irAEs of G2 and above, meaning that these toxicities, by
definition, could potentially lead to the need for life-long
treatment with a meaningful impact on patient quality
of life (Qol). We found no statistical association between
patients baseline characteristics (age and sex) and irAEs
onset and/or frisk of long-lasting toxicities.
Third, we demonstrated that a rigorous accounting of
toxicities onset, including late-onset ones, is critical to
assess the potential impact of irAEs on OS. While an
association between irAE development and response to
ICI(s) has been advocated in many retrospective studies
[28e30], in our series, no statistical association exists
between irAE occurrence and OS, both for advanced/
metastatic melanoma and LC. In fact, while comparing
OS between patients who experienced irAEs and pa-
tients who did not, HR from the standard Cox model
appears to be highly significant (suggesting better
outcome for patients experiencing toxicity), but the
difference is not significant when the toxicity is correctly
considered as a time-dependent covariate, see Fig. 4.
This could be explained by the well-known ‘immortal-
time bias’: patients who experienced late-onset toxicities
have a guaranteed survival up to the onset of that
toxicity. Of note, in the Mel cohort, the survival curve
for patients who experienced an irAE shows a distinctive
plateau after the 3-year mark (Fig. 4D, 23 patients at
risk). This could suggest a potential correlation of irAE
with long-term ICI benefit in a specific sub-group of Mel
patients. However, caution should be taken for the
interpretation of these results, as patients receiving
different treatments were pooled together in this survival
analysis. Unfortunately, subgroup analysis according to
irAE or treatment types led to insufficient numbers to
reach sufficient statistical power, precluding conclusions
as to whether a specific ICI regimen or irAE is associ-
ated with a better prognostic.
E. Ghisoni et al. / European Journal of Cancer 149 (2021) 153e164162However, some limitations of this study need to be
stated. First of all, our study focused only on melanoma
and lung cancer. Second, the use of text-based search
functions to screen for irAEs in electronic medical re-
cords that are not always populated by medical terms
from MedDRA (Medical Dictionary for Regulatory
Activities). In addition, the retrospective nature of the
study and the difficulty of irAE grading outside of
clinical trials could potentially lead to an underestima-
tion of irAEs. Last but least, the potential confounding
effect of immunosuppression on OS should be taken
into account. As the immunotherapy field is rapidly
advancing, we recognise that further studies, ideally
multicentre prospective ones, are urgently needed to
validate our findings across different tumour subtypes
and also in the adjuvant setting [28,31,32].
In conclusion, we demonstrated that in the immu-
notherapy era, initial clinical trial reports leading to ICI
approval should imperatively be followed by studies
with long-term follow-up of the same patients, as
incomplete reporting of duration and resolution of
toxicities certainly underestimates the clinical relevance
of irAEs. In this context, real-world evidence represents
an indispensable complement to clinical trials, as it
provides data on large numbers of patients on long time
scales at a fraction of the cost of clinical trials. In
addition, real-world evidence can help assess the gen-
eralisability of clinical trial findings to unselected patient
populations that are more faithful to real-life situations.
To our knowledge, this study is one of the first and
largest real-world data analysis evaluating the risk of
late-onset and long-term irAEs in unselected patients.
The reported evidence is a seminal example of how real-
world data can be harnessed to guide clinical decision
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